Considering (i) the potential mechanism of therapeutic effect on this disease, (ii) the well documented safety profile of the drug for rheumatologic indications and posologies, and its low cost (iii) its efficacy in reducing proteinuria in IgA nephropathy patients in a preliminary Chinese randomized control study, the investigators aim in this study at establishing the beneficial impact of hydroxychloroquine on IgA nephropathy in a double blind randomized controlled trial on a Caucasian French population with harder outcomes and a longer follow-up compared to the Chinese preliminary study. conditions: IgA Nephropathy studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: double blind trial randomized primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 334 type: ESTIMATED name: Hydroxychloroquine Oral Tablet name: Placebo oral tablet measure: Absolute difference in estimate Glomerular Filtration Rate (GFR) between hydroxychloroquine group and control group evolution measure: nephrological follow-up: proteinuria measure: nephrological follow-up: albuminuria measure: nephrological follow-up: GFR measure: nephrological follow-up: hematuria measure: nephrological follow-up: systolic and diastolic blood pressure measure: nephrological follow-up: proteinuria measure: nephrological follow-up: albuminuria measure: nephrological follow-up: GFR measure: nephrological follow-up: hematuria measure: nephrological follow-up: systolic and diastolic blood pressure measure: nephrological follow-up: proteinuria measure: nephrological follow-up: albuminuria measure: nephrological follow-up: hematuria measure: nephrological follow-up: systolic and diastolic blood pressure measure: end stage renal disease (GFR< 15mL/min/1.73m²) measure: death measure: adverse events (pruritus, gastro-intestinal disorders) and serious adverse events (QT enlargement, cardiomyopathy, ophthalmologic disorders, neuromyopathy, cytopenia) sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHU Gabriel Montpied city: Clermont-Ferrand zip: 63000 country: France lat: 45.77966 lon: 3.08628 facility: Hospices Civils de Lyon city: Lyon zip: 69437 country: France lat: 45.74848 lon: 4.84669 facility: AP-HM Hôpital de la Conception city: Marseille zip: 13385 country: France name: Thomas ROBERT, MD role: CONTACT phone: 0662426166 phoneExt: +33 email: thomas.robert@ap-hm.fr lat: 43.29551 lon: 5.38958 facility: APHP Hôpital Bichat city: Paris zip: 75018 country: France name: Eric DAUGAS, PU-PH role: CONTACT phone: 0140257101 phoneExt: +33 email: eric.daugas@aphp.fr lat: 48.85341 lon: 2.3488 facility: APHP Hôpital de Tenon city: Paris zip: 75020 country: France name: Khalil EL KAROUI, PU-PH role: CONTACT phone: 0156016317 phoneExt: +33 email: khalil.el-karoui@aphp.fr lat: 48.85341 lon: 2.3488 facility: CHU Lyon Sud city: Pierre-Bénite zip: 69495 country: France name: Sarah MEZAACHE, MD role: CONTACT phone: 0478863712 phoneExt: +33 email: sarah.mezaache@chu-lyon.fr lat: 45.7009 lon: 4.82511 facility: CHU de Saint-Etienne city: Saint-Étienne zip: 42055 country: France name: Nicolas MAILLARD, MD role: CONTACT phone: 0477828127 phoneExt: +33 email: nicolas.maillard@chu-st-etienne.fr name: Carine LABRUYERE role: CONTACT phone: 0477120469 phoneExt: +33 email: carine.labruyere@chu-st-etienne.fr lat: 45.43389 lon: 4.39 hasResults: False